QUOTE AND NEWS
Reuters  5 hrs ago  Comment 
European Union competition regulators will decide by July 29 whether U.S. drugmaker Mylan should be allowed to go ahead with its $34-billion hostile bid for Perrigo, the...
Market Intelligence Center  9 hrs ago  Comment 
After closing Wednesday at $189.16, Perrigo (PRGO) presents an attractive opportunity to get a 4.84% return in just 57 days, which is an annualized return of 30.99% (for comparison purposes only). To enter this trade, sell one Aug. '15 $185.00...
Reuters  Jun 24  Comment 
Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying...
newratings.com  Jun 24  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
Forbes  Jun 23  Comment 
In early trading on Tuesday, shares of Perrigo Company (PRGO) topped the list of the day's best performing components of the S&P 500 index, trading up 3.1%. Year to date, Perrigo Company registers a 14.0% gain.
newratings.com  Jun 23  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
Benzinga  Jun 23  Comment 
Analysts at BMO Capital initiated coverage on Perrigo Company plc Ordinary Shares (NYSE: PRGO) with a Outperform rating. The target price for Perrigo is set to $246. Perrigo shares have gained 27.50 percent over the past 52 weeks, while the...
newratings.com  Jun 22  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
TheStreet.com  Jun 17  Comment 
NEW YORK ( The Deal) -- Abbott Laboratories  said Tuesday said it would back Mylan's  proposed $35 billion unsolicited takeover offer for Perrigo . Abbott, which holds 14.5% of Mylan since its 2014 sale of non-U.S. developed markets in...




 

Perrigo Company is a global health-care supplier and the world's largest manufacturer of over-the-counter pharmaceuticals for the store brand market. The company develops, distributes, and manufactures over-the-counter and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients, and consumer products.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki